NAD⁺ and Sirtuins

1. Overview & Definition

Nicotinamide adenine dinucleotide (NAD⁺) is an essential pyridine nucleotide that functions as a coenzyme (cosubstrate) in redox reactions and as a substrate for multiple signaling enzymes. It exists in two forms: the oxidized form NAD⁺ and the reduced form NADH. A related molecule, NADP⁺/NADPH, serves similar functions in anabolic metabolism and antioxidant defense.

Beyond its classical role in energy metabolism, NAD⁺ serves as a substrate for three major classes of enzymes that regulate aging-related processes:

• Sirtuins (SIRT1–7): NAD⁺-dependent protein deacetylases that regulate metabolism, DNA repair, inflammation, and circadian rhythms
• Poly(ADP-ribose) polymerases (PARPs): DNA damage sensors that consume NAD⁺ during DNA repair
• CD38/CD157: Ectoenzymes that hydrolyze NAD⁺ to cyclic ADP-ribose (cADPR) and nicotinamide

NAD⁺ levels decline by approximately 50% between youth and old age in multiple tissues, contributing to impaired sirtuin and PARP function, reduced mitochondrial biogenesis, and accelerated aging phenotypes.

2. NAD⁺ Metabolism & Biosynthesis

2.1 De Novo Synthesis (Kynurenine Pathway)

Tryptophan is converted to NAD⁺ through the kynurenine pathway, a multi-step process involving enzymes such as indoleamine 2,3-dioxygenase (IDO), kynurenine 3-monooxygenase (KMO), and quinolinate phosphoribosyltransferase (QPRT). This pathway is relatively inefficient — approximately 60 mg of tryptophan is required to produce 1 mg of NAD⁺ — and is subject to regulation by inflammatory cytokines (IFN-γ upregulates IDO, diverting tryptophan away from NAD⁺ synthesis).

2.2 Salvage Pathway (Primary Route)

The salvage pathway recycles nicotinamide (NAM) back to NAD⁺ and is the predominant source of NAD⁺ in most mammalian tissues. The rate-limiting enzyme is nicotinamide phosphoribosyltransferase (NAMPT), which converts NAM to nicotinamide mononucleotide (NMN). NMN is then converted to NAD⁺ by nicotinamide mononucleotide adenylyltransferase (NMNAT).

NAMPT expression and activity decline with age, contributing to NAD⁺ depletion. NAMPT is also regulated by circadian rhythms (CLOCK:BMAL1 binding to the NAMPT promoter), linking NAD⁺ metabolism to the circadian clock.

2.3 Preiss-Handler Pathway

Nicotinic acid (niacin, vitamin B3) is converted to NAD⁺ through the Preiss-Handler pathway, involving nicotinic acid phosphoribosyltransferase (NAPRT), NMNAT, and NAD⁺ synthetase (NADSYN1). This pathway is active in the liver and kidney but less so in other tissues.

2.4 NAD⁺ Consumption

NAD⁺ is consumed by multiple competing pathways:

Pathway	Enzyme(s)	Function	NAD+ Consumption
Sirtuins	SIRT1–7	Protein deacetylation; metabolic regulation	1 NAD+ per deacetylation
PARPs	PARP1–16	DNA repair; transcriptional regulation	~200 NAD+ per PAR chain
CD38/CD157	CD38, CD157	Calcium signaling; immune regulation	Hydrolyzes NAD+ to NAM + ADPR
SARM1	SARM1	Axon degeneration	Hydrolyzes NAD+ to NAM + ADPR + cyclic ADPR
ARTs	ART1–5	Protein mono-ADP-ribosylation	1 NAD+ per mono-ADPR

3. The Sirtuin Family

Sirtuins are a conserved family of NAD⁺-dependent protein deacetylases (and ADP-ribosyltransferases) that regulate metabolism, stress resistance, DNA repair, and longevity. Mammals express seven sirtuins (SIRT1–7), each with distinct subcellular localizations, substrates, and functions:

Sirtuin	Localization	Primary Substrates	Key Functions
SIRT1	Nucleus, cytoplasm	p53, FOXO3a, PGC-1α, NF-κB, histones	Metabolic regulation; DNA repair; inflammation; circadian rhythm; longevity in model organisms
SIRT2	Cytoplasm	α-tubulin, FOXO3a, histone H4K16	Cell-cycle regulation; genomic stability; neuroprotection
SIRT3	Mitochondria	Acetyl-CoA synthetase 2, SOD2, IDH2, Complex I	Mitochondrial metabolism; ROS detoxification; thermogenesis
SIRT4	Mitochondria	GDH, PDH, MCD	Insulin secretion; amino acid metabolism; tumor suppression
SIRT5	Mitochondria	CPS1, HMGCS2, PDH	Urea cycle; ketogenesis; desuccinylation/demalonylation
SIRT6	Nucleus	Histone H3K9ac, H3K56ac, PARP1	DNA repair (BER, NHEJ); telomere maintenance; glucose homeostasis; longevity in mice
SIRT7	Nucleolus	Histone H3K18ac, p53, Nrf1	Ribosomal biogenesis; mitochondrial function; oncogenesis

3.1 SIRT1: The Master Regulator

SIRT1 is the most extensively studied sirtuin and is considered a central node in longevity signaling. SIRT1 deacetylates and thereby activates PGC-1α, promoting mitochondrial biogenesis and oxidative metabolism. It also deacetylates FOXO transcription factors, enhancing stress resistance and DNA repair. SIRT1-mediated deacetylation of NF-κB p65 suppresses inflammatory gene expression, while deacetylation of p53 dampens apoptosis and senescence signaling.

Resveratrol, a polyphenol found in red wine, was initially reported to activate SIRT1 directly, but subsequent studies demonstrated that this effect was assay-artifact dependent. More recent work has shown that resveratrol may activate SIRT1 indirectly through AMPK activation and PDE inhibition.

3.2 SIRT6: The Longevity Sirtuin

SIRT6 knockout mice exhibit a severe premature aging phenotype, dying within weeks from genomic instability, metabolic defects, and degenerative changes. Conversely, transgenic overexpression of SIRT6 extends lifespan in male mice by ~15%. SIRT6 promotes DNA double-strand break repair through both non-homologous end joining (NHEJ) and base excision repair (BER), and its deficiency leads to telomere dysfunction and accelerated aging.

4. NAD⁺ Decline with Aging

NAD⁺ levels decline progressively with age across multiple tissues. In human muscle, NAD⁺ content decreases by approximately 50% between ages 20 and 70. Similar declines have been observed in the brain, liver, skin, and adipose tissue.

4.1 Mechanisms of Decline

• Reduced NAMPT expression: NAMPT levels decline with age in multiple tissues, impairing the salvage pathway
• Increased CD38 activity: CD38 expression increases with age, particularly in immune cells and adipose tissue, accelerating NAD⁺ consumption
• Chronic PARP activation: Accumulated DNA damage with aging chronically activates PARP1, consuming NAD⁺
• Impaired circadian regulation: Disruption of CLOCK:BMAL1-mediated NAMPT transcription reduces nocturnal NAD⁺ synthesis
• Reduced physical activity: Exercise-induced NAMPT upregulation declines with sedentary behavior

4.2 Consequences of NAD⁺ Depletion

• Impaired sirtuin activity → reduced mitochondrial biogenesis, impaired DNA repair, increased inflammation
• Reduced PARP function → compromised DNA repair capacity
• Decreased metabolic flexibility → impaired fatty acid oxidation and glucose homeostasis
• Disrupted circadian rhythms → impaired sleep-wake cycles and metabolic oscillations
• Increased oxidative stress → reduced SOD2 activity (SIRT3 target)

5. NAD⁺ Precursor Supplementation

Multiple NAD⁺ precursors are available as dietary supplements and are being investigated for their ability to restore NAD⁺ levels and improve healthspan:

Precursor	Pathway	Bioavailability	Key Clinical Trials	Status
NMN (Nicotinamide mononucleotide)	Direct precursor to NAD+ (bypasses NAMPT)	Good oral bioavailability; enters cells via Slc12a8 transporter	Irie et al. (2020): NMN increased NAD+ in healthy men; Yoshino et al. (2021): Improved muscle insulin sensitivity in prediabetic women	Multiple Phase 2/3 trials ongoing
NR (Nicotinamide riboside)	Converted to NMN by NRK1/2, then to NAD+	Good oral bioavailability; some first-pass metabolism	Trammell et al. (2016): Elevated NAD+ in humans; Martens et al. (2018): Improved blood pressure and arterial stiffness in middle-aged adults	Phase 3 trials ongoing (ChromaDex)
Niacin (Nicotinic acid)	Preiss-Handler pathway	Good; limited by flushing side effect	Long history of use for dyslipidemia; raises NAD+ but with side effects	FDA-approved for dyslipidemia
NAM (Nicotinamide)	Salvage pathway (requires NAMPT)	Good; may inhibit sirtuins at high doses	Used in dermatology; less effective for NAD+ elevation than NMN/NR	Widely available; inexpensive
NA (Nicotinic acid)	Preiss-Handler pathway	Good; causes flushing via GPR109A	Long history of lipid-lowering use; raises NAD+	Available OTC and by prescription

5.1 NMN vs. NR: Current Evidence

Both NMN and NR effectively raise NAD⁺ levels in humans, but direct comparisons are limited. Key considerations:

• NMN may have higher bioavailability in some tissues due to the Slc12a8 transporter, which is highly expressed in the small intestine and brain
• NR has more extensive human clinical trial data and is GRAS-certified by the FDA
• Both precursors show similar NAD⁺ elevation (~40–100% increase) at doses of 250–1,000 mg/day
• Neither has demonstrated clear lifespan extension in humans; healthspan benefits are modest and inconsistent across studies

6. Clinical Evidence

6.1 Metabolic Health

A randomized controlled trial by Yoshino et al. (2021) in postmenopausal women with prediabetes demonstrated that 250 mg/day NMN for 10 weeks improved muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) and increased muscle NAD⁺ content. However, a larger trial by Yi et al. (2023) in overweight/obese adults found no significant improvement in insulin sensitivity with NR supplementation (2,000 mg/day for 12 weeks).

6.2 Cardiovascular Function

Martens et al. (2018) reported that NR supplementation (1,000 mg/day for 6 weeks) reduced systolic blood pressure and improved arterial stiffness (measured by carotid-femoral pulse wave velocity) in middle-aged and older adults. However, these findings have not been consistently replicated in all studies.

6.3 Physical Function

Multiple trials have examined the effects of NAD⁺ precursors on physical performance. Results have been mixed, with some studies showing modest improvements in walking speed and muscle strength, while others show no significant effect. The heterogeneity may reflect differences in baseline NAD⁺ status, dose, duration, and participant characteristics.

6.4 Cognitive Function

Preclinical studies in Alzheimer's disease models suggest that NAD⁺ restoration can improve cognitive function, reduce neuroinflammation, and decrease amyloid pathology. Human data are limited, but a small pilot study (N=30) of NR in older adults showed improvements in cognitive test performance and reduced neuroinflammatory markers in CSF.

7. Other NAD⁺-Consuming Enzymes

7.1 PARPs

Poly(ADP-ribose) polymerases (particularly PARP1 and PARP2) are DNA damage sensors that consume large amounts of NAD⁺ to synthesize poly(ADP-ribose) chains on target proteins. During acute DNA damage, PARP1 can deplete cellular NAD⁺ by >80% within minutes. Chronic low-level DNA damage with aging may create a state of "PARP hyperactivation" that competes with sirtuins for limited NAD⁺ pools.

7.2 CD38

CD38 is a type II transmembrane glycoprotein with NAD⁺ glycohydrolase activity. CD38 expression increases with age, particularly in immune cells and adipose tissue, and is a major driver of NAD⁺ decline. CD38 knockout mice have elevated NAD⁺ levels and improved metabolic function. CD38 inhibitors (e.g., apigenin, luteolin) are being investigated as NAD⁺-boosting strategies.

7.3 SARM1

Sterile alpha and TIR motif containing 1 (SARM1) is an NAD⁺ hydrolase that promotes axon degeneration after injury. SARM1 activation depletes axonal NAD⁺, triggering a cascade of metabolic failure and axon destruction. SARM1 inhibitors are in development for neurodegenerative diseases and traumatic brain injury.

8. References